Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Pozycja w akcjach #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Cena akcji
$0.03702159
Ostatnia synchronizacja: 2024-01-29
Kapitalizacja rynkowa
$7.21M
Zmiana (1 dzień)
-3.08%
Zmiana (1 rok)
0.00%
Kraj
AU
Handel Antisense Therapeutics Limited (ANP)

Kategoria

Historia stopy dywidendy dla Antisense Therapeutics Limited (ANP)
Stopa dywidendy (TTM) dla Antisense Therapeutics Limited (symbol akcji: ANP) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Antisense Therapeutics Limited (ANP) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji